Today marks an important milestone at Novo Nordisk Pharmatech as we announce the launch of TrypsiNNex® – a new recombinant enzyme in the company portfolio. This product represents a key part of our growth strategy in the specialty enzymes sector for pharmaceutical manufacturing. TrypsiNNex® is a sustainable, animal-free trypsin product that will enable the production of medicines for patients worldwide. At Novo Nordisk Pharmatech, our commitment to providing superior pharmaceutical materials continues to drive our innovation and global impact.
“With the launch of TrypsiNNex®, we are expanding our product portfolio within the exciting field of enzymes. This is part of our global strategy and ambition to be a trusted scientific partner, delivering superior pharmaceutical materials in a sustainable way,” says Ulla Grove Krogsgaard Thomsen, chief executive officer at Novo Nordisk Pharmatech A/S.
In recent years, we have discovered numerous opportunities for improvement in trypsin-based biopharmaceutical production. These opportunities, when addressed, can significantly enhance the reliability and efficiency of biomanufacturers who utilize animal-source or recombinant trypsin in their production processes:
- By moving away from animal-source trypsin, biopharmaceutical production can reduce risk of contamination in the final drug product, thereby enhancing product safety and quality.
- By ensuring low batch-to-batch variability manufacturing consistency can also improve. Addressing trypsin autolysis can maintain activity and specificity during storage and use, thereby boosting production consistency and reliability.
- Finally, the biomanufacturer’s supply chain can increase resilience by strengthening the sourcing of raw materials. Global instabilities highlight the importance of robust supply chains, and trypsin, as a critical raw material used in processes such as vaccine production, can benefit from such improvements.
TrypsiNNex® serves as a key ingredient in biomanufacturing processes such as cell dissociation, virus activation, and insulin production. The product possesses the following unique advantages:
- TrypsiNNex® is a new animal-free, recombinant trypsin, which is essential to ensure reduced risk of contamination in bioprocessing. By reducing risk, we support our customers in delivering higher product safety and quality while saving cost on virus mitigation processes.
- It improves process consistency by offering high purity and high concentration of β-trypsin. The high β-trypsin content increases the enzyme specificity and longevity. It provides a more predictable and consistent performance in its application.
- TrypsiNNex® is manufactured with carefully controlled processes that comply with excipient GMP level, to ensure a consistent, high-potency recombinant trypsin. Adhering to a high-quality standard supports our customers in creating safer products, ultimately benefiting patients and users globally.
You can read more about TrypsiNNex® on our product page here.
